- Home
- PASG vs ANTX Comparison
PASG vs ANTX Comparison
Compare PASG & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PASG | ANTX |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3M | 31.2M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PASG | ANTX |
|---|---|---|
| Price | $8.90 | $1.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $34.50 | $2.00 |
| AVG Volume (30 Days) | 57.7K | ★ 72.6K |
| Earning Date | 03-03-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.12 | $1.00 |
| 52 Week High | $20.00 | $1.55 |
Technical Indicators
Market Signals| Indicator | PASG | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 42.36 |
| Support Level | $8.86 | $1.06 |
| Resistance Level | $10.63 | $1.14 |
| Average True Range (ATR) | 1.38 | 0.05 |
| MACD | -0.45 | -0.01 |
| Stochastic Oscillator | 1.46 | 12.11 |
Price Performance
Historical ComparisonAbout PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.